For families and patients wanting more information about Allo Phase 2 Clinical Trial: LEARN MORE

For symptomatic peri- and post menopausal women interested in information regarding clinical trial to test the safety and efficacy of PhytoSERM, a potential alternative to hormone therapy. LEARN MORE

Parkinson’s Disease (PD)

 

By the time the symptoms of Parkinson’s disease appear, more than 70% of dopaminergic neurons have already been lost. Current therapies focus primarily on symptomatic control, while therapeutics or biomarkers targeting the earliest stages of the disease are non-existent. Across age-associated neurodegenerative diseases, therapeutic development must focus on both the discovery of meaningful biomarkers of disease stage, as well as compounds capable of slowing or halting the degenerative process.

 

Our pre-clinical work has identified a critical period when endogenous regeneration of neural stem cells rapidly declines. This period is associated with decreased expression of Nrf2, a protein responsible for protecting neurons from oxidative damage and inflammation. We are working to develop Nrf2-based targets into compounds capable of restarting neural regeneration.

 

In parallel, we have developed a powerful new drug discovery platform using induced pluripotent stem cells (iPSCs) and fibroblasts from patients with neurodegenerative diseases.

 

Housing more than 100 samples from individuals across the spectrum of age-associated neurodegenerative disorders – CIBS is leveraging this resource to develop and evaluate patient-specific therapeutics and biomarkers.

The Center for Innovation in Brain Science (CIBS) at the University of Arizona is addressing the challenge that, in the 21st century, there is not a single cure for a single neurodegenerative disease and is focused on four age-associated neurodegenerative diseases: Alzheimer’s, Parkinson’s, Multiple Sclerosis and ALS.

© 2021 Center for Innovation Brain Science. University of Arizona Health Sciences.